Parties, docket activity and news coverage of federal case LA JOLLA PHARMACEUTICAL COMPANY et al v. GLAND PHARMA LIMITED, case number
Innoviva to acquire La Jolla Pharma.
A brand-new press release revealed that La Jolla Pharmaceutical (LJPC) has agreed to be acquired by Innovia (INVA). La Jolla Pharmaceutical will become a subsidiary of Innoviva, and La
LA JOLLA PHARMACEUTICAL COMPANY et al v. GLAND PHARMA LIMITED (2:22-cv- ), New Jersey District Court, Filed: - PacerMonitor
La Jolla Pharmaceutical (NASDAQ:LJPC) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) have entered into a definitive merger agreement, under which La Jolla would acquire Tetraphase, through a tender
About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to
Larry Edwards is a seasoned pharmaceutical La Jolla Pharmaceuticals and Tetraphase Pharmaceuticals, a subsidiary of La Jolla Pharmaceutical Company.
Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma Inc, PharmaIN Corporation, Baxter International Inc, La Jolla Pharmaceutical Company
(RTTNews) - Innoviva Inc. (INVA) agreed to acquire La Jolla Pharmaceutical Co. (LJPC). It will pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume
Comments
Thanks and keep writing